Daniel A. Lang

Partner

Daniel A. Lang

New York

+1 212 459 7095

Daniel Lang is a partner in Goodwin’s Technology and Life Sciences groups and co-chair of the firm’s Technology practice in New York. He has extensive experience advising high-growth technology and life sciences companies and investors that focus on these companies. His practice spans the corporate lifecycle, covering startup formations; seed, venture capital, and growth equity financings; joint ventures; strategic collaborations; mergers and acquisitions (M&A); and IPOs, PIPEs, and other capital markets transactions. Daniel also regularly advises clients on corporate governance, securities laws compliance, and other external “general counsel” matters.

Experience

Daniel represents companies and investors in the technology and life sciences sectors, including AI, e-commerce, consumer products, beauty and fashion, sports, media and entertainment, consumer and enterprise software, cybersecurity, defense tech, deep tech, adtech, fintech, insurtech, real estate tech, medtech, digital health, wellness, healthcare, and biotechnology.

Representative clients include private companies AllDigital Specialty Insurance, Another Tomorrow, Bem!, BetMGM, Biteable, Carebridge, Chord Commerce, Coderbyte, Enlaye, Glossier, Hibercell, Instant Teams, JLo Beauty, KaloCyte, Main Street Rural, Mejuri, Nirvana, Novakid, Paperless Post, Pathway Labs, ReSupply, Revivn, Sakara, Supply Energetics, Thrive Global, Tradewell Technologies, and Wave Sports + Entertainment; and investment funds Ally Bridge Group, Alpha Wave Global, Avego, BEVC, B Capital, Eden Global Partners, Glasswing Ventures, Norrsken VC, Nyca Partners, Perceptive Advisors, Qiming Venture Partners, RA Capital, Rosalind Advisors, Spice Expeditions, Vivo Capital, Walter Ventures, and White Star Capital.

Representative Matters

Transcend Therapeutics in its acquisition by Otsuka
Prevu in its acquisition by reAlpha
Color Wow in its acquisition by L’Oréal
Carebridge in its acquisition by Elevance Health
TRC 2004 in its acquisition by Candid Therapeutics
Avvir in its acquisition by Hexagon AB
Pyramid Biosciences in its acquisition by Biohaven
Pond5 in its acquisition by Shutterstock
Tara Biosystems in its acquisition by Valo Health
Celtra in its acquisition by Symphony Technology Group
Thrive Global in its founding and financing of Thrive AI Health with Open AI, acquisitions of Boundless Mind and ZP Group, and strategic collaboration with Walmart
Talla in its acquisition by Seva
StreetLinx in its acquisition by Symphony
Citus Health in its acquisition by Brightree, a subsidiary of ResMed
arfa in its acquisition of Yaguara
Hibercell in its acquisition of Biothera Pharmaceuticals’ Imprime PGG program
Syntimmune in its acquisition by Alexion Pharmaceuticals
Aspire Health in its acquisition by Anthem
Orchard Platform in its acquisition by Kabbage
Glossier in its acquisition of Dynamo E-Media
Thar Pharmaceuticals in its acquisition by Grünenthal
Songza in its acquisition by Google
M5 Networks in its acquisition by ShorTel
XGraph in its acquisition by Add This (formerly Clearspring)
Fidelis Security Systems in its acquisition by General Dynamics
Nomi Technologies in its acquisition by Brickstream
Tagman in its acquisition by Ensighten
EveryScreen Media in its acquisition by Media6Degrees
Fairhaven Capital in the acquisition of its portfolio company, CrowdTwist, by Oracle

Glossier in its financings by Lone Pine Capital, IVP, Thrive Capital, Forerunner, and Index Ventures
Thrive Global in various financings by Kleiner Perkins, Owl Ventures, JAZZ Venture Partners, IVP, Marc Benioff, Ray Dalio, and Kevin Durant
Chord Commerce in its financings by Eclipse Ventures, Foundation Capital, M13, and Equal
Instant Teams in its financings by Tiger Global and Squadra
Nirvana in its financings by Northzone, Inspired, Eniac VC, and Surface
Paperless Post in its financings by August Capital, Sherpalo Ventures, RRE Ventures, Mousse Partners, and Top Tier
Pathway Labs in its financing by AlleyCorp and Breyer Capital
Avvir in its financings by Trust Ventures, Khosla Ventures, MetaProp, and Stacked Capital
Biteable in its Series A financing led by Cloud Apps Capital Partners
Prevu in its financing led by Alpaca
Celtra in its financings by WPP, Unilever, Grandbanks Capital, and Fairhaven Capital
Digital Power Optimization Partners in its financing by NYDIG
Orchard Platform in its financing by Thrive Capital, Spark Capital, and Canaan Partners
Hubble Contacts in its financings by First Mark, Two River, Wildcat Capital Management, Founders Fund, Greycroft, and Colgate
Aircall in its financings by Draper Esprit, Next World Capital, Balderton Capital, and eFounders
Linkwell Health in various financings with participation by HLM Venture Partners and Spark Capital
Even Financial in its financing led by Canaan Partners and Lerer Hippeau Ventures
Pond5 in its financing by Accel Partners and Stripes Group
arfa in its financings by Forerunner, Index, White Star Capital, Thrive, Box Group, and others
Megaphone TV in its financing led by Softbank Korea

Glasswing Ventures in investments, including Asepha, Basetwo, Cydelphi, Infinity Loop, Iris, Inrupt, Krane, Kusari, Labviva, Narrative, Reprise, Retrocausal, Sigma, ShipAngel, Telmai, Trustle, and Verusen
B Capital in various investments, including Cadence, Carlsmed, Carrick, Hotspot Therapeutics, JUDI Health, Lively, Nalu, Numerion, PicnicHealth, Sift, Tiny Health, and Volastra
Ally Bridge Group in various investments, including Advancell, Alumis, Epicrispr, Ensho, Profound Bio, and Vital Connect
Alpha Wave Global in various investments, including Anthropic, Attralus, Biolinq, CognitionAI, COUR Pharma, Histosonics, Moonwalk, Ramp, and Transcend Therapeutics
Perceptive Advisors in various investments, including Dynacure, Athira Pharma, Kindbody, Freenome, and AavantiBio
Spice Expeditions in various investments, including Cashea, Midas, Imprint, Plata Card, and Salmon

Codiak BioSciences in its $83 million IPO and $66 million follow-on offering
Foundation Medicine in its (i) $120 million IPO, (ii) collaboration and equity transaction with Roche, with total value in excess of $1 billion, and (iii) sale of the remaining minority interest to Roche for $2.4 billion
Ocera Therapeutics in its (i) acquisition by Mallickrodt for up to $117 million in upfront cash and contingent (CVR) consideration, (ii) $28 million PIPE financing, (iii) $25 million public offering, and (iv) $25 million “at-the-market” offering facility
Allena Pharmaceuticals in its $75 million IPO
Chiasma in its (i) $102 million IPO, (ii) $34.5 million follow-on offering, (iii) $55 million follow-on offering, (iv) $70 million follow-on offering, and (v) acquisition by Amryt
J.P. Morgan in (i) the $184 million IPO, (ii) a $116 million follow-on offering, (iii) a $230 million follow-on offering, (iv) a $200 million “at-the-market” offering facility, and (v) a $200 million convertible note offering of Intrexon
Vivo Capital in investments in ASLAN Pharmaceuticals, BioPharmX, Strongbridge Pharma, Kadmon, MEI Pharma, Sierra Oncology, Selecta BioSciences, Unicycive, Delcath, and Gracell
RA Capital as lead investor in $240 million PIPE financing of Cidara
Intralinks, Tranzyme, and Tengion in their IPOs

Areas of Practice

Professional Activities

Daniel is a frequent lecturer at the Cardozo Tech Law Startup Clinic, Columbia Business School, Columbia Law School, and Cornell Tech.

Credentials

Education

JD

Benjamin N. Cardozo School of Law

BA

Tufts University

Admissions

Bars

New York
New Jersey

Recognition & Awards

Daniel was named a New York Metro Rising Star by Super Lawyers. In law school, Daniel was an articles editor of the Cardozo Law Review.

Daniel A. Lang

Experience

Representative Matters

Mergers and Acquisitions

Company-Side Private Financings

Investor-Side Private Financings

Public Company Transactions

Areas of Practice

Professional Activities

Credentials

Education

JD

BA

Admissions

Bars

Recognition & Awards

Related Content

The Competition for AI’s Scarcest Resource

Why the AI Race Hinges on Elite Talent

Delaware Court Awards More Than $180 Million for Breach of Commercially Reasonable Efforts Obligation in Drug Development Milestone Dispute